UBS Group’s Peak Bio, Inc. Common Stock PKBO Stock Holding History

UBS Group’s Portfolio PKBO Stock Details PKBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-719	Closed	-$3.01K	–	11522
2022 Q4	$3.01K	Sell	719 -1,662	-70%	-$11.5K	﹤0.01%	9582
2022 Q3	$24K	Hold	2,381	–	–	﹤0.01%	7181
2022 Q2	$23K	Sell	2,381 -190	-7%	-$1.87K	﹤0.01%	6728
2022 Q1	$25K	Buy	2,571 +571	+29%	+$5.6K	﹤0.01%	7220
2021 Q4	$19K	Buy	2,000 +500	+33%	+$4.89K	﹤0.01%	7943
2021 Q3	$15K	Buy	+1,500	New	+$14.6K	﹤0.01%	7546

Other funds holding PKBO

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

UBS Group's PKBO Position: Q1 2023 in Review

UBS Group sold out of Peak Bio, Inc. Common Stock (PKBO) in Q1 2023, closing a stake of 719 shares — an estimated $3.01K sold.

UBS Group first reported a position in PKBO in Q3 2021 and held it in 6 quarters. The position peaked at $25K in Q1 2022. 1 fund tracked by Wall St. Rank holds PKBO as of Q1 2023.

UBS Group reported no remaining Peak Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
UBS Group sold 719 Peak Bio, Inc. Common Stock shares in Q1 2023, an estimated $3.01K.
UBS Group first reported a position in Peak Bio, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
UBS Group's Peak Bio, Inc. Common Stock position peaked at $25K in Q1 2022.
1 fund tracked by Wall St. Rank held Peak Bio, Inc. Common Stock as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.